Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 1, 2016, Pages 196-207

  Abdul Aziz, Mohd H ^a   Lipman, Jeffrey ^a,b   Akova, Murat ^c   Bassetti, Matteo ^d   De Waele, Jan J ^e   Dimopoulos, George ^f   Dulhunty, Joel ^a,b   Kaukonen, Kirsi Maija ^g   Koulenti, Despoina ^a,f   Martin, Claude ^h,i   Montravers, Philippe ^j   Rello, Jordi ^k   Rhodes, Andrew ^l,aw   Starr, Therese ^b   Wallis, Steven C ^a   Roberts, Jason A ^a,b   Paul, Sanjoy ^a   Ribas, Antonio Margarit ^m   De Crop, Luc ^e   Spapen, Herbert ⁿ   Wauters, Joost ^o   Dugernier, Thierry ^p   Jorens, Philippe ^q   Dapper, Ilse ^r   De Backer, Daniel ^s   Taccone, Fabio S ^s   Ruano, Laura ^k   Afonso, Elsa ^t,u   Alvarez Lerma, Francisco ^v   Gracia Arnillas, Maria Pilar ^v   Fernández, Francisco ^w   Feijoo, Neus ^x   Bardolet, Neus ^x   Rovira, Assumpta ^x   Garro, Pau ^y   Colon, Diana ^y   Castillo, Carlos ^z   Fernado, Juan ^z   Lopez, Maria Jesus ^aa   Fernandez, Jose Luis ^aa   Arribas, Ana Maria ^aa   Teja, Jose Luis ^ab   Ots, Elsa ^ab   Montejo, Juan Carlos ^ac   Catalan, Mercedes ^ac   Prieto, Isidro ^ad   Gonzalo, Gloria ^ad   Galvan, Beatriz ^ae   Blasco, Miguel Angel ^af   Meyer, Estibaliz ^af   Nogal, Frutos Del ^af   Vidaur, Loreto ^ag   Sebastian, Rosa ^ag   Garde, Pila Marco ^ag   Velasco, Maria del Mar Martin ^ah   Crespo, Rafael Zaragoza ^ai   Esperatti, Mariano ^u,aj   Torres, Antoni ^u,aj   Baldesi, Olivier ^i,ak   Dupont, Herve ^al   Mahjoub, Yazine ^i,al   Lasocki, Sigismond ^am   Constantin, Jean Michel ^i,am   Payen, Jean François ^i,an   Albanese, Jacques ^h,i   Malledant, Yannick ^ao   Pottecher, Julien ^i,ap   Lefrant, Jean Yves ^i,aq   Jaber, Samir ^i,ar   Joannes Boyau, Olivier ^i,as   Orban, Christophe ^i,at   Ostermann, Marlies ^au   McKenzie, Catherine ^au   Berry, Willaim ^au   Smith, John ^au   Lei, Katie ^au   Rubulotta, Francesca ^av   Gordon, Anthony ^av   Brett, Stephen ^av   Stotz, Martin ^av   Templeton, Maie ^av   Ebm, Claudia ^aw   Moran, Carl ^aw   Pettilä, Ville ^g   Xristodoulou, Aglaia ^f   Theodorou, Vassiliki ^ax   Kouliatsis, Georgios ^ax   Sertaridou, Eleni ^ax   Anthopoulos, Georgios ^ay   Choutas, George ^ay   Rantis, Thanos ^ay   Karatzas, Stylianos ^ay   Balla, Margarita ^ay   Papanikolaou, Metaxia ^ay   Myrianthefs, Pavlos ^az   Gavala, Alexandra ^az   Fildisis, Georgios ^az   Koutsoukou, Antonia ^ba   Kyriakopoulou, Magdalini ^ba   Petrochilou, Kalomoira ^ba   Kompoti, Maria ^bb   Michalia, Martha ^bb   Clouva Molyvdas, Fillis Maria ^bb   Gkiokas, Georgios ^bc   Nikolakopoulos, Fotios ^bc   Psychogiou, Vasiliki ^bc   Malliotakis, Polychronis ^bd   Akoumianaki, Evangelia ^bd   Lilitsis, Emmanouil ^bd   Koulouras, Vassilios ^be   Nakos, George ^be   Kalogirou, Mihalis ^be   Komnos, Apostolos ^bf   Zafeiridis, Tilemachos ^bf   Chaintoutis, Christos ^bf,bg   Arvaniti, Kostoula ^bg   Matamis, Dimitrios ^bg   Kydona, Christina ^bg   Gritsi Gerogianni, Nikoleta ^bg   Giasnetsova, Tatiana ^bg   Giannakou, Maria ^bh   Soultati, Ioanna ^bh   Chytas, Ilias ^bh   Antoniadou, Eleni ^bi   Antipa, Elli ^bi   Lathyris, Dimitrios ^bi   Koukoubani, Triantafyllia ^bj   Paraforou, Theoniki ^bj   Spiropoulou, Kyriaki ^bj   Bekos, Vasileios ^bk   Spring, Anna ^bk   Kalatzi, Theodora ^bk   Nikolaou, Hara ^bb   Laskou, Maria ^bb   Strouvalis, Ioannis ^bb   Aloizos, Stavros ^ay   Kapogiannis, Spyridon ^ay   Soldatou, Ourania ^ay   Adembri, Chiara ^bl   Villa, Gianluca ^bl   Giarratano, Antonio ^bm   Raineri, Santi Maurizio ^bm   Cortegiani, Andrea ^bm   Montalto, Francesca ^bm   Strano, Maria Teresa ^bm   Marco Ranieri, V ^bn,br   Sandroni, Claudio ^bo   De Pascale, Gennaro ^bo   Molin, Alexandre ^bp   Pelosi, Paolo ^bp   Montagnani, Luca ^bq   Urbino, Rosario ^br   Mastromauro, Ilaria ^br   De Rosa, Francesco G ^br   Cardoso, Teresa ^bs   Afonso, Susana ^bt   Gonçalves Pereira, João ^bu   Baptista, João Pedro ^bv   Özveren, Arife ^c   more..

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c HACETTEPE UNIVERSITY   (Turkey)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h HÔPITAL NORD   (France)

ⁱ AzuRea Group   (France)

^j BICHAT HOSPITAL   (France)

^k UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^l ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^m HOSPITAL NOSTRA SENYORA DE MERITXELL   (Andorra)

ⁿ UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p Clinique Saint Pierre of Ottignies   (Belgium)

^q ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^r AZ Monica   (Belgium)

^s ERASME HOSPITAL   (Belgium)

^t HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^u INSTITUTO DE SALUD CARLOS III   (Spain)

^v HOSPITAL DEL MAR   (Spain)

^w Centro Medico Delfos   (Spain)

^x HOSPITAL GENERAL DE CATALUNYA   (Spain)

^y HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^z HOSPITAL TXAGORRITXU   (Spain)

^aa HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^ab HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^ac HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^ad HOSPITAL RAMÓN Y CAJAL   (Spain)

^ae HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^af HOSPITAL SEVERO OCHOA   (Spain)

^ag HOSPITAL DONOSTIA   (Spain)

^ah HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^ai HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^aj HOSPITAL CLÍNIC   (Spain)

^ak CENTRE HOSPITALIER DU PAYS D AIX   (France)

^al AMIENS UNIVERSITY HOSPITAL   (France)

^am ANGERS UNIVERSITY HOSPITAL   (France)

^an GRENOBLE UNIVERSITY HOSPITAL   (France)

^ao PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^ap UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^aq NÎMES UNIVERSITY HOSPITAL   (France)

^ar MONTPELLIER UNIVERSITY HOSPITAL   (France)

^as BORDEAUX UNIVERSITY HOSPITAL   (France)

^at UNIVERSITY HOSPITAL OF NICE   (France)

^au ST THOMAS HOSPITAL   (United Kingdom)

^av IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^aw ST GEORGE S HOSPITAL   (United Kingdom)

^ax DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^ay KAT HOSPITAL   (Greece)

^az Centre for the Prevention of Breast Cancer   (Greece)

^ba SOTIRIA GENERAL HOSPITAL   (Greece)

^bb IASO GENERAL HOSPITAL   (Greece)

^bc UNIVERSITY OF ATHENS   (Greece)

^bd Herakleion University Hospital   (Greece)

^be UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^bf General Hospital of Larisa   (Greece)

^bg Aristotle University of Thessaloniki   (Greece)

^bh AHEPA UNIVERSITY HOSPITAL   (Greece)

^bi Department of Anesthesiology   (Greece)

^bj General Hospital of Trikala   (Greece)

^bk ATHENS NAVAL HOSPITAL   (Greece)

^bl CAREGGI UNIVERSITY HOSPITAL   (Italy)

^bm UNIVERSITY OF PALERMO   (Italy)

^bn Section of Geriatrics   (Italy)

^bo CATHOLIC UNIVERSITY   (Italy)

^bp UNIVERSITY OF GENOA   (Italy)

^bq UNIVERSITY OF GENOA   (Italy)

^br Azienda Ospedaliero Universitaria San Giovanni Battista di Torino   (Italy)

^bs HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^bt HOSPITAL DE SANTO ANTÓNIO DOS CAPUCHOS   (Portugal)

^bu HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^bv CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; THIENAMYCIN DERIVATIVE;

ABDOMINAL INFECTION; ADULT; ARTICLE; BLOODSTREAM INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CONTINUOUS INFUSION; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); POST HOC ANALYSIS; RESPIRATORY TRACT INFECTION; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE; SURVIVAL TIME; URINARY TRACT INFECTION; AGED; ANALOGS AND DERIVATIVES; BLOOD ANALYSIS; CLINICAL TRIAL; CRITICAL ILLNESS; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BLOOD CHEMICAL ANALYSIS; CRITICAL ILLNESS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; THIENAMYCINS; TREATMENT OUTCOME;

EID: 84960122710     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv288     Document Type: Article

References (48)

1. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501.
2. De Waele J, Carlier M, Hoste E et al. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiol 2014; 80: 1302-9.
3. Roberts JA, Kirkpatrick CM, Roberts MS et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35: 156-63.
4. Roberts JA, Kirkpatrick CM, Roberts MS et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
5. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
6. Felton TW, Hope WW, Roberts JA. How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it? Diagn Microbiol Infect Dis 2014; 79: 441-7.
7. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41: 489-95.
8. Roberts JA, Paul SK, Akova M et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58: 1072-83.
9. Abdul-Aziz MH, Dulhunty JM, Bellomo R et al. Continuous β-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care 2012; 2: 37.
10. Yang H, Zhang C, Zhou Q et al. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. PLoS One 2015; 10: e0116769.
11. Teo J, Liew Y, Lee W et al. Prolonged infusion versus intermittent boluses of β-lactam antibiotics for treatment of acute infections: a meta-analysis. Int J Antimicrob Agents 2014; 43: 403-11.
12. Shiu J, Wang E, Tejani AM et al. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev 2013; issue 3: CD008481.
13. Chant C, Leung A, Friedrich JO. Optimal dosing of antibiotics in critically ill patients using continuous/extended infusions: a systematic review and meta-analysis. Crit Care 2013; 17: R279.
14. Korbila IP, Tansarli GS, Karageorgopoulos DE et al. Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis. Expert Rev Anti Infect Ther 2013; 11: 585-95.
15. Falagas ME, Tansarli GS, Ikawa K et al. Clinical outcomes with extended or continuous versus short-termintravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56: 272-82.
16. Tamma PD, Putcha N, Suh YD et al. Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 2011; 11: 181.
17. Roberts JA, Webb S, Paterson D et al. A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit Care Med 2009; 37: 2071-8.
18. Kasiakou SK, Sermaides GJ, Michalopoulos A et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5: 581-9.
19. Roberts JA, De Waele JJ, Dimopoulos G et al. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis 2012; 12: 152.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. Dulhunty JM, Roberts JA, Davis JS et al. Continuous infusion of β-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56: 236-44.
22. Chytra I, Stepan M, Benes J et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012; 16: R113.
23. Roberts JA, Boots R, Rickard CMet al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007; 59: 285-91.
24. Jamal JA, Roberts DM, Udy AA et al. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents 2015; 46: 39-44.
25. Jamal JA, Mat-Nor MB, Mohamad-Nor FS et al. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents 2015; 45: 41-5.
26. Boselli E, Breilh D, Rimmele T et al. Alveolar concentrations of piperacillin/ tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 2008; 36: 1500-6.
27. Briscoe SE, Mc Whinney BC, Lipman J et al. Amethod for determining the free (unbound) concentration of ten β-lactamantibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 907: 178-84.
28. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-63.
29. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care 2011; 15: R206.
30. Abdul-Aziz MH, Lipman J, Mouton JW et al. Applying pharmacokinetic/ pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 2015; 36: 136-53.
31. Muller AE, Punt N, Mouton JW. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Antimicrob Agents Chemother 2014; 58: 2512-9.
32. Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 2013; 68: 900-6.
33. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
34. Huttner A, Von Dach E, Renzoni A et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Int J Antimicrob Agents 2015; 45: 385-92.
35. Carlier M, Carrette S, Roberts JA et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 2013; 17: R84.
36. Udy AA, Varghese JM, Altukroni M et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-9.
37. Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol 2011; 7: 539-43.
38. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R et al. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008; 36: 674-80.
39. Hsaiky L, Murray KP, Kokoska L et al. Standard versus prolonged doripenem infusion for treatment of Gram-negative infections. Ann Pharmacother 2013; 47: 999-1006.
40. Lorente L, Jimenez A, Martin MM et al. Clinical cure of ventilatorassociated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009; 33: 464-8.
41. Lorente L, Jimenez A, Palmero S et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007; 29: 2433-9.
42. MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2014; 58: 1359-64.
43. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
44. Jamal JA, Economou CJ, Lipman J et al. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012; 18: 460-71.
45. Roberts JA, Roberts MS, Robertson TA et al. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 2009; 37: 926-33.
46. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 1993; 31 Suppl D: 1-16.
47. Houck PM, Bratzler DW, Nsa W et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with communityacquired pneumonia. Arch Intern Med 2004; 164: 637-44.
48. Hanes SD, Demirkan K, Tolley E et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002; 35: 228-35.